Baxter International Inc. (BAX) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Baxter International Inc. (BAX) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Baxter International: Debt, Margin Pressure, Dreadful FY26 Guidance (Downgrade)
Baxter International faces a fundamental downturn after weak Q4 results and a dismal FY 2026 guide, prompting a hold rating downgrade. BAX trades at a very cheap valuation, but persistent margin compression, debt risks, and repeated earnings disappointments overshadow near-term recovery prospects. Despite some growth in Advanced Surgery and new connected care offerings, operational efficiency and profitability remain under severe pressure.
BAX Stock Falls Following Q4 Earnings Miss, Margins Contract
Baxter International misses Q4 EPS estimates as margins shrink, even as revenues top forecasts; shares slide 12.5% on weak 2026 guidance.
Baxter (BAX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Baxter International (BAX) Q4 Earnings Lag Estimates
Baxter International (BAX) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.58 per share a year ago.
Baxter to Post Q4 Earnings: What's in Store for the Stock?
BAX's fourth-quarter results are likely to reflect muted revenue growth and an EPS decline due to ongoing infusion therapy and IV fluid headwinds.
Reasons to Retain Baxter International Stock in Your Portfolio Now
BAX is reshaping its portfolio following the divestiture of its Kidney Care business, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.
The Bottom Fishing Club - Baxter: Defensive Pick, Restructuring And Paying Down Debt
Baxter International offers a compelling defensive play, trading at historically low valuations after significant deleveraging and operational headwinds. BAX's forward cash earnings multiple is around 8x, notably cheaper than hospital and consumer health product peers, despite slightly weaker gross profit margins. Management's focus on debt reduction and cost controls positions BAX for margin expansion and potential sales growth into 2027.
Baxter Unveils Dynamo Smart Stretcher to Improve Hospital Safety
BAX introduces its Dynamo Series smart stretcher, aiming to boost hospital safety and reduce patient transfers.
Baxter International Inc. (BAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Baxter International Inc. (BAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Reasons to Retain Baxter International Stock in Your Portfolio Now
BAX is reshaping its portfolio following the divestiture of Kidney Care, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.
BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care
Baxter shows EMR-integrated smart pumps cut safety alerts and speed IV setup, backed by real-world data from over a million infusions at ASHP 2025.
